Status:
WITHDRAWN
Periperal Blood Lymphocytes During Prostate RT
Lead Sponsor:
University Health Network, Toronto
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Right now it is not possible to predict which patients are going to react more to RT. Many things could affect patient's response to radiation. One of the factors is whether the person can repair dama...
Eligibility Criteria
Inclusion
- Intermediate-risk prostate cancer patients (T1/T2N0M0 with either GS \< 7 and PSA between 10-20 ng/ml or GS 7 and PSA less than 20 ng/ml).
- Planned for radical RT to the prostate with IMRT planning (79Gy/39fractions or 60 Gy/20 fractions).
- No contraindications to diagnostic CT scanning.
- Prostate volumes will be less than 80 cc to control the planning dose volume histogram (DVH) as much as possible in terms of rectal and bladder volumes.
- No known DNA repair disorders (e.g. family history of AT, BRCA1/2 or Li Fraumeni syndrome) or contraindications to radical pelvic RT.
Exclusion
- Inability to provide informed consent.
- Patient having contraindications to diagnostic CT scan.
- Patients who have unobtainable data regarding previous therapy and their clinical outcome.
- Patients should not have any diagnostic X-rays or CAT scans 2 weeks prior to their enrollment into the study.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01899391
Start Date
August 1 2009
End Date
March 1 2013
Last Update
July 15 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.